Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOMP: SBRT and Oncolytic Virus + Pembrolizumab in TNBC and NSCLC
NCT03004183Phase 2Completed
- Sponsor
- Houston Methodist Research Institute
- Start
- Jul 2017
- Primary completion
- Jul 2022
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aglatimagene besadenovec in triple-negative breast cancer (TNBC), sponsored by Houston Methodist Research Institute. Primary endpoint: Objective Response Rate. Started Jul 2017; status: completed.
02
Drugs
aglatimagene besadenovec
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03004183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03004183.